{
    "nctId": "NCT03147040",
    "briefTitle": "AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer",
    "officialTitle": "AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 23,
    "primaryOutcomeMeasure": "Number of patients free of progression at 6 months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed and written informed consent\n* Age 18 year or older\n* Metastatic or incurable locally advanced lobular breast cancer with confirmation of the lobular histology and E-cadherin loss on a biopsy of a metastatic lesion.\n* Metastatic lesion accessible for histological biopsies\n* Evidence of progression of disease\n* A maximum of two lines of palliative chemotherapy\n* WHO performance status of 0 or 1\n* Evaluable disease or measurable according to RECIST 1.1\n\nExclusion Criteria:\n\n* Leptomeningeal disease localization\n* History of having received other anticancer therapies within 2 weeks of start of the study drug\n* History of immunodeficiency, autoimmune disease, conditions requiring immunosuppression\n* Prior treatment with immune checkpoint blockade\n* Live vaccine within 2 weeks prior to start of study\n* Active other cancer\n* Active hepatitis B",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}